ZANOSAR- streptozocin powder, for solution 
ESTEVE PHARMACEUTICALS, S.A.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Zanosar (Streptozocin) powder, for injection (Esteve SAS)

Dear Health Care Provider Letter

D-1

D-2

D-3

D-4

How supplied

NDC 68118-100-01: Each vial contains 1g Streptozocin Powder for concentrate for solution for infusion. Each carton contains 1 vial.

Vial Label Vial Label

Carton Label Carton Label

ZANOSAR 
streptozocin powder, for solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:68118-100
Route of AdministrationINTRAVENOUS
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
STREPTOZOCIN (UNII: 5W494URQ81) (STREPTOZOCIN - UNII:5W494URQ81) STREPTOZOCIN1 g  in 10 mL
Inactive Ingredients
Ingredient NameStrength
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)  
SODIUM HYDROXIDE (UNII: 55X04QC32I)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:68118-100-011 in 1 CARTON02/01/2023
110 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug for use in drug shortage02/01/2023
Labeler - ESTEVE PHARMACEUTICALS, S.A. (460023922)

Revised: 4/2023
Document Id: f87746a1-78c9-df32-e053-6294a90a80da
Set id: f31d3bff-6fc6-c35f-e053-2995a90a596b
Version: 2
Effective Time: 20230403
 
ESTEVE PHARMACEUTICALS, S.A.